PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

ViGeneron and Daiichi Sankyo to develop therapy for eye diseases

Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate vgAAV-based therapeutic candidates

ViGeneron and Daiichi Sankyo have agreed to a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vGAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases.

The two companies have been working on a programme together since early 2021. The follow-on collaboration allows them to create and validate vgAAV-based therapeutic candidates for the undisclosed target through in vivoanimal studies.

ViGeneron’s two novel vgAAV vectors were identified and characterised through a unique and stringent in vivoselection procedure, where an AAV2-based peptide-display library was intravenously administered in mouse models followed by the isolation of vector DNA from target cells after only 24 hours.

“Based on our partnership and findings, to date, we look forward to a successful follow-on collaboration with Daiichi Sankyo and potentially to developing a new sustained therapy that will address a dire need for many patients suffering from prevalent eye diseases,” commented Dr Caroline Man Xu, co-founder and CEO of ViGeneron.

“Furthermore, the advancement of our research agreement exemplifies the potential of our intravitreally injected vgAAV vectors for large and commercially significant disease areas,” she added.

ViGeneron is currently advancing its proprietary gene therapy pipeline to treat ophthalmic diseases while partnering with leading biopharmaceutical players in retinal diseases, central nervous system conditions and other disease areas. The company’s two novel next-generation gene therapy platforms are geared towards addressing the limitations of existing adeno-associated virus (AAV)-based gene therapies.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026